Gilead refuses to sell HIV drug lenacapavir to MSF

Medicines charity group MSF (Medecins Sans Frontieres/Doctors Without Borders) reported that US drugmaker Gilead Sciences (Nasdaq: GILD) has refused to sell MSF supplies of lenacapavir, Gilead’s patented HIV prevention and treatment drug of transformative potential, for use in MSF’s humanitarian programs.

According to an open letter MSF sent Gilead, the drugmaker cites its arrangement with the Global Fund to provide lenacapavir for two million people as “all the supply available to low- and middle-income countries.”